Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of $31.00.

Emily Bodnar has given his Buy rating due to a combination of factors tied to the emerging clinical profile of Olvi-Vec in difficult-to-treat lung cancers. In the SCLC study, the combination of Olvi-Vec with platinum chemotherapy is showing encouraging signs of activity in a heavily pretreated, platinum-relapsed population that typically has very low response rates. The latest data not only add an additional partial responder, but also suggest a dose-related improvement at the highest dose level, which appears to be a strong candidate for the regimen to be advanced into later-stage testing. Importantly, several patients are demonstrating prolonged progression-free survival relative to their prior therapies despite only receiving a single cycle of Olvi-Vec and no maintenance immunotherapy, which points to potential durability of benefit and an ability to overcome platinum resistance.

Emily Bodnar’s rating is based on the view that these early but favorable efficacy and durability signals, combined with a manageable safety profile so far, support meaningful upside potential for Genelux. The early NSCLC data, while still in the initial stages of follow-up, further reinforce the drug’s potential by showing disease control in patients who have already failed both platinum chemotherapy and checkpoint inhibitors, an area of high unmet need. The use of a dose in NSCLC that matches the most active SCLC cohort provides a rational bridge between the programs and could streamline development if positive trends continue. Collectively, these factors underpin the conviction that Olvi-Vec can emerge as a differentiated therapy in relapsed/refractory lung cancer and justify maintaining a Buy recommendation on GNLX shares.

Bodnar covers the Healthcare sector, focusing on stocks such as Agios Pharma, Atossa Therapeutics, and AnaptysBio. According to TipRanks, Bodnar has an average return of 11.8% and a 34.67% success rate on recommended stocks.